Although we cannot entirely explain the lack of a more robust effect of BTZ alone on IκBα levels, important factors might have led to this unexpected finding including: 1) type of cells; Jurkat (leukemic blasts) vs. HuT 78 (malignant mature lymphoma cells); 2) concentration of BTZ; and 3) duration of treatment by BTZ. Here, CASC3 is linked to lymphoma.